{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T14:21:59Z","timestamp":1789741319842,"version":"4.0.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"This study was sponsored by Arrowhead Pharmaceuticals."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41591-026-04307-8","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T09:03:49Z","timestamp":1775552629000},"page":"1432-1443","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Zodasiran for cholesterol and triglyceride lowering in patients with hyperlipidemia: final report of phase 1 basket trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2276-1524","authenticated-orcid":false,"given":"Gerald F.","family":"Watts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4307-6748","authenticated-orcid":false,"given":"John","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Clifton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Given","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2974-9635","authenticated-orcid":false,"given":"Stacey","family":"Melquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5185-3666","authenticated-orcid":false,"given":"Daniel","family":"Gaudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8701-2201","authenticated-orcid":false,"given":"Ira J.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1922-7240","authenticated-orcid":false,"given":"Joshua W.","family":"Knowles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0905-2806","authenticated-orcid":false,"given":"Nicholas J.","family":"Leeper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2861-5325","authenticated-orcid":false,"given":"Robert A.","family":"Hegele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6432-1730","authenticated-orcid":false,"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"4307_CR1","doi-asserted-by":"crossref","unstructured":"Giugliano, R. P. et al. Clinical efficacy and safety of evolocumab in high-risk patients receiving a statin: secondary analysis of patients with low LDL cholesterol levels and in those already receiving a maximal-potency statin in a randomized clinical trial. JAMA Cardiol. 2, 1385\u20131391 (2017).","DOI":"10.1001\/jamacardio.2017.3944"},{"key":"4307_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11883-020-00846-8","volume":"22","author":"A Hussain","year":"2020","unstructured":"Hussain, A., Ballantyne, C. M., Saeed, A. & Virani, S. S. Triglycerides and ASCVD risk reduction: recent insights and future directions. Curr. Atheroscler. Rep. 22, 25 (2020).","journal-title":"Curr. Atheroscler. Rep."},{"key":"4307_CR3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","volume":"41","author":"U Laufs","year":"2020","unstructured":"Laufs, U., Parhofer, K. G., Ginsberg, H. N. & Hegele, R. A. Clinical review on triglycerides. Eur. Heart J. 41, 99\u2013109c (2020).","journal-title":"Eur. Heart J."},{"key":"4307_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach, F. et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 41, 111\u2013188 (2020).","journal-title":"Eur. Heart J."},{"key":"4307_CR5","doi-asserted-by":"crossref","unstructured":"Parhofer, K.G. et al. Expert opinion on the integration of combination therapy into the treatment algorithm for the management of dyslipidaemia. Eur. Heart J. Cardiovasc. Pharmacother. 11, 367\u2013379 (2025).","DOI":"10.1093\/ehjcvp\/pvaf007"},{"key":"4307_CR6","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1093\/eurheartj\/ehaf074","volume":"46","author":"AT Nordestgaard","year":"2025","unstructured":"Nordestgaard, A. T. et al. Expanding the triglyceride range in clinical trials: therapeutic opportunities. Eur. Heart J. 46, 1835\u20131848 (2025).","journal-title":"Eur. Heart J."},{"key":"4307_CR7","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.jacc.2023.02.038","volume":"81","author":"D Choi","year":"2023","unstructured":"Choi, D., Malick, W. A., Koenig, W., Rader, D. J. & Rosenson, R. S. Familial hypercholesterolemia: challenges for a high-risk population: JACC focus seminar 1\/3. J. Am. Coll. Cardiol. 81, 1621\u20131632 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"4307_CR8","doi-asserted-by":"publisher","first-page":"106857","DOI":"10.1016\/j.phrs.2023.106857","volume":"194","author":"NSR Lan","year":"2023","unstructured":"Lan, N. S. R., Bajaj, A., Watts, G. F. & Cuchel, M. Recent advances in the management and implementation of care for familial hypercholesterolaemia. Pharmacol. Res. 194, 106857 (2023).","journal-title":"Pharmacol. Res."},{"key":"4307_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2217\/fca-2021-0096","volume":"18","author":"GF Watts","year":"2022","unstructured":"Watts, G. F., Raal, F. J. & Chan, D. C. Transcriptomic therapy for dyslipidemias utilizing nucleic acids targeted at ANGPTL3. Future Cardiol. 18, 143\u2013153 (2022).","journal-title":"Future Cardiol."},{"key":"4307_CR10","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1194\/jlr.RA120000888","volume":"61","author":"RC Adam","year":"2020","unstructured":"Adam, R. C. et al. Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance. J. Lipid Res. 61, 1271\u20131286 (2020).","journal-title":"J. Lipid Res."},{"key":"4307_CR11","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nrendo.2017.119","volume":"13","author":"S Kersten","year":"2017","unstructured":"Kersten, S. Angiopoietin-like 3 in lipoprotein metabolism. Nat. Rev. Endocrinol. 13, 731\u2013739 (2017).","journal-title":"Nat. Rev. Endocrinol."},{"key":"4307_CR12","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","volume":"363","author":"K Musunuru","year":"2010","unstructured":"Musunuru, K. et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N. Engl. J. Med. 363, 2220\u20132227 (2010).","journal-title":"N. Engl. J. Med."},{"key":"4307_CR13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1612790","volume":"377","author":"FE Dewey","year":"2017","unstructured":"Dewey, F. E. et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N. Engl. J. Med. 377, 211\u2013221 (2017).","journal-title":"N. Engl. J. Med."},{"key":"4307_CR14","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1194\/jlr.P039875","volume":"54","author":"I Minicocci","year":"2013","unstructured":"Minicocci, I. et al. Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis. J. Lipid Res. 54, 3481\u20133490 (2013).","journal-title":"J. Lipid Res."},{"key":"4307_CR15","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","volume":"69","author":"NO Stitziel","year":"2017","unstructured":"Stitziel, N. O. et al. ANGPTL3 deficiency and protection against coronary artery disease. J. Am. Coll. Cardiol. 69, 2054\u20132063 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"4307_CR16","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","volume":"383","author":"FJ Raal","year":"2020","unstructured":"Raal, F. J. et al. Evinacumab for homozygous familial hypercholesterolemia. N. Engl. J. Med. 383, 711\u2013720 (2020).","journal-title":"N. Engl. J. Med."},{"key":"4307_CR17","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","volume":"383","author":"RS Rosenson","year":"2020","unstructured":"Rosenson, R. S. et al. Evinacumab in patients with refractory hypercholesterolemia. N. Engl. J. Med. 383, 2307\u20132319 (2020).","journal-title":"N. Engl. J. Med."},{"key":"4307_CR18","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1001\/jamacardio.2023.2921","volume":"8","author":"RS Rosenson","year":"2023","unstructured":"Rosenson, R. S. et al. Longer-term efficacy and safety of evinacumab in patients with refractory hypercholesterolemia. JAMA Cardiol. 8, 1070\u20131076 (2023).","journal-title":"JAMA Cardiol."},{"key":"4307_CR19","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41591-023-02222-w","volume":"29","author":"RS Rosenson","year":"2023","unstructured":"Rosenson, R. S. et al. Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial. Nat. Med. 29, 729\u2013737 (2023).","journal-title":"Nat. Med."},{"key":"4307_CR20","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1161\/CIRCULATIONAHA.118.039107","volume":"140","author":"Z Ahmad","year":"2019","unstructured":"Ahmad, Z. et al. Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia. Circulation 140, 470\u2013486 (2019).","journal-title":"Circulation"},{"key":"4307_CR21","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.122.059266","volume":"145","author":"BA Bergmark","year":"2022","unstructured":"Bergmark, B. A. et al. Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: translate-timi 70. Circulation 145, 1377\u20131386 (2022).","journal-title":"Circulation"},{"key":"4307_CR22","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","volume":"41","author":"D Gaudet","year":"2020","unstructured":"Gaudet, D. et al. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. Eur. Heart J. 41, 3936\u20133945 (2020).","journal-title":"Eur. Heart J."},{"key":"4307_CR23","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1093\/eurjpc\/zwae090","volume":"31","author":"A Zimerman","year":"2024","unstructured":"Zimerman, A. et al. Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: an analysis from the translate-timi 70 trial. Eur. J. Prev. Cardiol. 31, 1216\u20131223 (2024).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"4307_CR24","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/j.jacl.2019.04.033","volume":"13","author":"SC Wong","year":"2019","unstructured":"Wong, S. C. et al. Personalized medicine for dyslipidemias by RNA interference-mediated reductions in apolipoprotein c3 or angiopoietin-like protein 3. J. Clin. Lipidol. 13, e15 (2019).","journal-title":"J. Clin. Lipidol."},{"key":"4307_CR25","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1038\/s41591-023-02494-2","volume":"29","author":"GF Watts","year":"2023","unstructured":"Watts, G. F. et al. RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts. Nat. Med. 29, 2216\u20132223 (2023).","journal-title":"Nat. Med."},{"key":"4307_CR26","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa2404147","volume":"391","author":"RS Rosenson","year":"2024","unstructured":"Rosenson, R. S. et al. Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia. N. Engl. J. Med. 391, 913\u2013925 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4307_CR27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S2213-8587(25)00290-6","volume":"14","author":"F Raal","year":"2026","unstructured":"Raal, F. et al. Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia: results from the phase 2, randomised, open-label gateway trial. Lancet Diabetes Endocrinol. 14, 123\u2013136 (2026).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"4307_CR28","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/j.jacc.2025.03.005","volume":"85","author":"KK Ray","year":"2025","unstructured":"Ray, K. K. et al. Effect of ANGPTL3 inhibition with solbinsiran in preclinical and early human studies. J. Am. Coll. Cardiol. 85, 1803\u20131818 (2025).","journal-title":"J. Am. Coll. Cardiol."},{"key":"4307_CR29","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/S0140-6736(25)00507-0","volume":"405","author":"KK Ray","year":"2025","unstructured":"Ray, K. K. et al. Durability and efficacy of solbinsiran, a galnac-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (prolong-ang3): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 405, 1594\u20131607 (2025).","journal-title":"Lancet"},{"key":"4307_CR30","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1016\/j.jacc.2025.03.008","volume":"85","author":"X Xie","year":"2025","unstructured":"Xie, X. et al. Angiopoietin-like 3 antibody therapy in patients with suboptimally controlled hyperlipidemia: a phase 2 study. J. Am. Coll. Cardiol. 85, 1821\u20131835 (2025).","journal-title":"J. Am. Coll. Cardiol."},{"key":"4307_CR31","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.jacl.2012.08.007","volume":"6","author":"JB Christian","year":"2012","unstructured":"Christian, J. B. et al. Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg\/dl in patients with severe hypertriglyceridemia. J. Clin. Lipidol. 6, 450\u2013461 (2012).","journal-title":"J. Clin. Lipidol."},{"key":"4307_CR32","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1093\/clinchem\/hvad094","volume":"69","author":"SEJ Hansen","year":"2023","unstructured":"Hansen, S. E. J., Varbo, A., Nordestgaard, B. G. & Langsted, A. Hypertriglyceridemia-associated pancreatitis: new concepts and potential mechanisms. Clin. Chem. 69, 1132\u20131144 (2023).","journal-title":"Clin. Chem."},{"key":"4307_CR33","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s40256-024-00649-1","volume":"24","author":"HS Rangwala","year":"2024","unstructured":"Rangwala, H. S. et al. Evaluating the effectiveness and safety of evinacumab in treating hypercholesterolemia and hypertriglyceridemia: a systematic review and meta-analysis of randomized controlled trials. Am. J. Cardiovasc. Drugs 24, 523\u2013535 (2024).","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"4307_CR34","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1161\/CIRCULATIONAHA.123.065866","volume":"148","author":"L D\u2019Erasmo","year":"2023","unstructured":"D\u2019Erasmo, L. et al. ANGPTL3 deficiency and risk of hepatic steatosis. Circulation 148, 1479\u20131489 (2023).","journal-title":"Circulation"},{"key":"4307_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102152","volume":"6","author":"A Fappi","year":"2025","unstructured":"Fappi, A. et al. Effect of complete, lifelong ANGPTL3 deficiency on triglyceride-rich lipoprotein kinetics. Cell Rep. Med. 6, 102152 (2025).","journal-title":"Cell Rep. Med."},{"key":"4307_CR36","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.atherosclerosis.2017.08.031","volume":"268","author":"YX Xu","year":"2018","unstructured":"Xu, Y. X. et al. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol. Atherosclerosis 268, 196\u2013206 (2018).","journal-title":"Atherosclerosis"},{"key":"4307_CR37","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1056\/NEJMoa1701329","volume":"377","author":"MJ Graham","year":"2017","unstructured":"Graham, M. J. et al. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N. Engl. J. Med. 377, 222\u2013232 (2017).","journal-title":"N. Engl. J. Med."},{"key":"4307_CR38","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2404143","volume":"391","author":"CM Ballantyne","year":"2024","unstructured":"Ballantyne, C. M. et al. Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia. N. Engl. J. Med. 391, 899\u2013912 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4307_CR39","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","volume":"9","author":"D Gaudet","year":"2024","unstructured":"Gaudet, D. et al. Plozasiran (aro-apoc3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial. JAMA Cardiol. 9, 620\u2013630 (2024).","journal-title":"JAMA Cardiol."},{"key":"4307_CR40","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1038\/s41591-025-03830-4","volume":"31","author":"D Gaudet","year":"2025","unstructured":"Gaudet, D. et al. Targeting the angiopoietin-like protein 3\/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial. Nat. Med. 31, 2632\u20132639 (2025).","journal-title":"Nat. Med."},{"key":"4307_CR41","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/j.jacc.2025.02.035","volume":"85","author":"AT Nordestgaard","year":"2025","unstructured":"Nordestgaard, A. T. et al. Target populations for novel triglyceride-lowering therapies. J. Am. Coll. Cardiol. 85, 1876\u20131897 (2025).","journal-title":"J. Am. Coll. Cardiol."},{"key":"4307_CR42","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/eurheartj\/ehx317","volume":"39","author":"GR Thompson","year":"2018","unstructured":"Thompson, G. R. et al. Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. Eur. Heart J. 39, 1162\u20131168 (2018).","journal-title":"Eur. Heart J."},{"key":"4307_CR43","unstructured":"Tybj\u00e6rg-Hansen, A. & Nordestgaard, B. G. in Clinical Lipidology: A Companion to Braunwald\u2019s Heart Disease 3rd edn (ed. Ballantyne, C. M.) Ch. 4 (Elsevier, 2023)."},{"key":"4307_CR44","unstructured":"Manual of Laboratory Operations: Lipid and Lipoprotein Analysis (revised) Report No. (NIH) 75-67815 (US Government Printing Office, 1982)."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04307-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04307-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04307-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T14:02:41Z","timestamp":1776780161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04307-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4307"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04307-8","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.F.W. reports travel support from Arrowhead Pharmaceuticals and an institutional grant\/contract from Novartis. D.S. reports honoraria from Regeneron, Amgen, AstraZeneca, Amarin, Esperion, Novartis and Sanofi for serving on advisory boards. J.H., B.G., S.M. and R.Z. are Arrowhead Pharmaceuticals employees and shareholders. D.G. reports grants and\/or contracts from 89 bio, Alnylam Pharmaceuticals Inc., Inversago Pharma, Merck, New Amsterdam Pharma, Ultragenyx Pharmaceutical Inc. and Verve Therapeutics; research grants to ECOGENE-21 from Amgen, Amryt Pharma Holdings Ltd, Applied Therapeutics, Arrowhead Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, DalCor Pharmaceuticals, Eli Lilly and Company, Esperion Therapeutics, Inc., Ionis Pharmaceuticals, Inc., Kowa Pharmaceuticals America, Inc., National Research Council Canada, Novo Nordisk, Regeneron Pharmaceuticals, Inc., The Medicines Company and uniQure Biopharma B.V.; and consulting for Amgen, Amryt Pharma Holdings Ltd, Arrowhead Pharmaceuticals, CRISPR Therapeutics, Eli Lilly and Company, Flagship Pioneering, Ionis Pharmaceuticals, Inc., Medison Pharma, Novartis, Ultragenyx Pharmaceutical Inc. and Verve Therapeutics. I.J.G. reports being a consultant for Arrowhead Pharmaceuticals and Ionis. N.J.L. has received research funding from the National Institutes of Health, American Heart Association and the Greathouse Foundation; he is cofounder and board director of Bitterroot Bio; and consultant for Arrowhead Pharmaceuticals, Inc., Regeneron, MingSight Pharmaceuticals and Janssen. R.A.H. reports consulting for Acasti, Akcea Therapeutics, Inc., Amgen Canada, Arrowhead Pharmaceuticals, HLS Therapeutics Inc., Ionis, Medison, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi Pasteur Biologics LLC, Theratech and Ultragenyx Pharmaceutical Inc., as well as past consulting for Aegerion Pharmaceuticals, Inc. (prior to 2020). C.M.B. reports grants and\/or consultant fees from Arrowhead Pharmaceuticals during the conduct of the study; grants from Amgen, Ionis, Lilly, Merck, New Amsterdam and Novo Nordisk; and consultant fees from Ionis, Amgen, Lilly, Merck, New Amsterdam, Novo Nordisk, Amarin, Pfizer, Abbott Diagnostics, AstraZeneca, Denka Seiken, Genentech, Roche Diagnostics and Sanofi-Synth\u00e9labo. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}